Current Diagnosis and Management of Enteric Fever
Diagnosis
Blood culture remains the reference standard for diagnosing enteric fever, though its sensitivity is suboptimal. 1, 2, 3
Diagnostic Approach
Blood culture is the primary diagnostic method for confirming Salmonella Typhi or Paratyphi infection, despite sensitivity limitations (often <60% in real-world settings). 2, 3
Bone marrow culture offers higher sensitivity than blood culture but is rarely performed due to its invasive nature. 3
Clinical diagnosis is challenging because enteric fever presents with nonspecific symptoms: gradual fever onset over 3-7 days, malaise, headache, and myalgia that overlap with other febrile illnesses endemic to the same regions. 3
The Widal serological test, historically used in Africa and resource-limited settings, is not recommended due to poor sensitivity and specificity; when blood culture is unavailable, diagnosis should rely on clinical findings plus ruling out other febrile illnesses rather than Widal alone. 4
No reliable diagnostic tests exist for identifying asymptomatic chronic carriers, who serve as major reservoirs of infection. 2, 5
Key Clinical Pitfall
Previous antimicrobial use can significantly alter clinical presentation, making diagnosis even more difficult. 3 Maintain high clinical suspicion in patients returning from South Asia or other endemic areas with unexplained fever, even if symptoms are atypical. 1
Management
Azithromycin is the preferred first-line treatment for uncomplicated enteric fever in most settings, particularly where fluoroquinolone resistance is prevalent. 6, 7, 3
Antibiotic Selection Algorithm
For Fully Susceptible Strains (Increasingly Rare):
- Fluoroquinolones (ciprofloxacin, ofloxacin, gatifloxacin) were historically first-line but should now be avoided for infections originating from South Asia due to widespread resistance. 6, 3
For Nalidixic Acid-Resistant or Fluoroquinolone-Resistant Strains (Common):
Azithromycin is superior to fluoroquinolones with lower clinical failure rates (OR 0.48,95% CI 0.26-0.89), shorter hospital stays (-1.04 days), and lower relapse rates compared to ceftriaxone (OR 0.09,95% CI 0.01-0.70). 6
Ceftriaxone (third-generation cephalosporin) is an alternative second-line option, particularly for severe cases requiring parenteral therapy. 6, 3
Cefixime (oral third-generation cephalosporin) can be used for outpatient management when azithromycin is unavailable. 6
For Extensively Drug-Resistant (XDR) Typhoid (Pakistan Outbreak Strain):
Azithromycin and/or meropenem are required as XDR strains show resistance to fluoroquinolones, third-generation cephalosporins, and older agents. 1, 7
Combination therapy with azithromycin plus cefixime is being evaluated in the ACT-SA trial to target both intracellular and extracellular bacteria. 7
Tebipenem (oral carbapenem) represents a promising alternative requiring clinical evaluation. 7
Resistance Patterns by Region
Antibiotic choice must be guided by local resistance patterns, which vary dramatically: 8
- Ampicillin susceptibility: 3-97% (varies by country)
- Ciprofloxacin susceptibility: 9-95%
- Chloramphenicol susceptibility: 4-94%
- Ceftriaxone resistance is now common in Pakistan 3
Treatment Duration and Route
Oral therapy is appropriate for outpatient management of uncomplicated cases in endemic regions where most patients are treated. 7
Parenteral therapy (ceftriaxone or meropenem) should be reserved for severely ill patients, those with complications, or confirmed XDR infections. 6, 3
Management of Chronic Carriers
There is insufficient evidence to guide antimicrobial management of chronic fecal carriers, though longer courses of antibiotics are typically attempted. 1, 7
Complications Requiring Monitoring
Life-threatening complications typically arise in the second week of untreated illness and include: 3
- Intestinal perforation
- Gastrointestinal bleeding
- Encephalopathy/confusion
- Bone and joint infections
Prevention
Typhoid conjugate vaccines (TCVs) provide the most effective prevention, showing large reductions in acute typhoid fever (RR 0.20,95% CI 0.12-0.32) with minimal adverse events. 9
TCVs are more effective and provide longer protection (up to 4 years) compared to older Vi polysaccharide and Ty21a vaccines. 9, 8
Vaccination should be administered at least a few weeks before travel to endemic areas. 1
No vaccine currently exists for paratyphoid fever, though development is underway based on genetic similarities with S. Typhi. 8, 5
Water, sanitation, and hygiene measures remain cornerstones of prevention alongside vaccination. 3